Advanced metastatic triple-negative breast cancer (TNBC) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Metastatic triple-negative breast cancer (TNBC) is a distinct and immensely complex form of breast cancer. Among all subtypes of breast cancers, TNBC has a comparatively high rate of relapse, a high rate of distant metastasis, and poor overall survival after standard chemotherapy. TNBC is a heterogeneous disease encompassing a variety of biomarkers or genomic signatures; it accounts for 12% of all breast cancers in the USA. 1- and 2- year survival rates are 75% and 55%, respectively. Prognosis is poor in the advanced stages – median survival of 13.3 months following diagnosis of metastatic TNBC. •Emerging therapies are expected to drive patient stratification for biomarker-defined and pathway-specific (subtyping) patient subgroups - an opportunity for a novel agent in relevant specific segments. TNBC is a clinicopathologic, not intrinsic (genomically defined) subgroup, as neither overexpressing ER and PR nor is HER2+ (IHC and FISH). Neither hormonal (endocrine) nor HER2-targeted therapies are indicated Potential for FastTrack/ breakthrough designation with promising outcomes in the biomarker-driven patient segment; Several PARP inhibitors are in trials; veliparib+carboplatin followed by chemotherapy showed PCR: 52% vs. 26% (chemotherapy alone) 40% of TNBC show overexpression of GPNMB; unusual activity with glembatumumab, a GPNMB-targeting AD Biomarker-driven segments have been identified within TNBC, with POC. A better understanding of these would enable personalized treatment with improved patient outcomes. p53, PTEN, and PIK3CA are most frequently mutated in TNBC (>10%).

 

The competitive landscape of Advanced metastatic triple-negative breast cancer (TNBC) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Advanced metastatic triple-negative breast cancer (TNBC) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Advanced metastatic triple-negative breast cancer (TNBC) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Advanced metastatic triple-negative breast cancer (TNBC) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          Trodelvy®         Everest Medicines         Phase 2

2          Atezolizumab (MPDL3280A)      Hoffmann-La Roche      Phase 3

3          Nanosomal Docetaxel Lipid Suspension Jina Pharmaceuticals Inc.            Phase 3

4          Trilaciclib           G1 Therapeutics, Inc.    Phase 2

5          ladiratuzumab vedotin    Seagen Inc.      Phase 1

6          X4P-001           Abbisko Therapeutics Co, Ltd    Phase 2

7          TJ107 +Pembrolizumab I-Mab Biopharma Co. Ltd.          Phase 2

8          Ipatasertib        MedSIR            Phase 2

9          niraparib           Tesaro, Inc.      Phase 1

10        PQR309           PIQUR Therapeutics AG            Phase 2

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more